Delaware lawmakers approve corporate bill that critics call giveaway to billionaires
The law, known as SB 21, was approved by a vote by
The bill mostly impacts companies with a controlling shareholder, like Meta Platforms , which is controlled by Zuckerberg. The proposal provides steps that allow for a company and its controlling shareholder to arrange deals, such as selling corporate assets to the controller, that cannot be challenged in court by the company's other investors.
Supporters and opponents of the bill both agreed during Tuesday's debate that the state must prevent "DExit" -- or a stampede of companies moving their legal home out of one of the country's smallest and least populated states -- although they disagreed on the strategy. While other states are trying to attract corporations,
The state's corporate legal system, which locals refer to as "the franchise," generates more than 20% of
"We have a million Delawareans who rely on the
Several companies, mostly with controlling shareholders, have said they might or will leave
The proposed legislation has been labeled "the billionaire's bill" by critics, which include attorneys for shareholders and managers of pension funds. High-profile opposition ads included a billboard truck featuring an image of
Witnesses who testified for opponents said the bill might prompt shareholders to encourage companies to leave
The bill prevents shareholders from challenging deals that are approved by a board committee that has a majority of independent directors or by a vote by public shareholders. The bill also limits records available to shareholders who want to investigate a deal for conflicts.
Numerous amendments were rejected, including one that would have eliminated the law's retroactive effective date. The law will be effective back to
Corporate leaders have expressed frustration in recent years over court rulings that upset certain expectations about the state's law. Musk fueled the debate last year by urging companies to follow Tesla and leave the state after a
(Reporting by
(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Related News
-
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Benzinga - 24 minutes ago
-
Rosenberg Research Sees "Big" Negative Hit to Canada's Economy From Latest U.S. Auto Tariffs
MT Newswires - 26 minutes ago
-
Exclusive-Energy trader Vitol eyes $3 billion sale of US shale producer, sources say
Reuters - 28 minutes ago
-
Wishpond Collaborating With Venops
MT Newswires - 30 minutes ago
-
Former Meta executives raise $15 million for AI assistant startup
Reuters - 32 minutes ago
-
Bicycle Therapeutics Names Felix J. Baker as Chairman
MT Newswires - 33 minutes ago
-
Market Chatter: China Server Maker H3C Short Running Short of Nvidia Chips
MT Newswires - 34 minutes ago